ArticleAdvances in pharmacological sciences2013
Interactions among Low Dose of Methotrexate and Drugs Used in the Treatment of Rheumatoid Arthritis.
Article in Advances in pharmacological sciences, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Efficacy of Monotherapy with Biologics and JAK Inhibitors for the Treatment of Rheumatoid Arthritis: A Systematic Review.Advances in therapy · 2018Pooled it
- A comprehensive review on thermo-responsive targeted and functional therapy for management of rheumatoid arthritis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Anti-Drug Antibodies in the Biological Therapy of Autoimmune Rheumatic Diseases.Journal of clinical medicine · 2023Review
- Hydrogels for the treatment of rheumatoid arthritis.Frontiers in bioengineering and biotechnology · 2022Review
- A Unique Interaction of Methotrexate and Nitrofurantoin Resulting in Irreversible Pulmonary Fibrosis.Cureus · 2022Article
- Drug interactions in the treatment of rheumatoid arthritis and psoriatic arthritis.Rheumatology international · 2020Review
- Real-world questions and concerns about disease-modifying antirheumatic drugs (DMARDs): a retrospective analysis of questions to a medicine call center.BMC rheumatology · 2020Article
- Optimising low-dose methotrexate for rheumatoid arthritis-A review.British journal of clinical pharmacology · 2019Review
- Drug-related problems in patients with rheumatoid arthritis.Therapeutics and clinical risk management · 2019Article
- Article
- Factors Associated with Myelosuppression Related to Low-Dose Methotrexate Therapy for Inflammatory Rheumatic Diseases.PloS one · 2016Article
- Stevens Johnson Syndrome-Toxic Epidermal Necrolysis Overlap Secondary to Interaction Between Methotrexate and Etoricoxib: A Case Report.Journal of clinical and diagnostic research : JCDR · 2015Article
- Vitamin C enhances anticancer activity in methotrexate‑treated Hep3B hepatocellular carcinoma cells.Oncology reports · 2014Article
- Skin rash during treatment with generic itraconazole.Journal of pharmacology & pharmacotherapeutics · 2014Article
- Safety and efficacy of generic drugs with respect to brand formulation.Journal of pharmacology & pharmacotherapeutics · 2013Article
- Pharmacovigilance and drug safety in Calabria (Italy): 2012 adverse events analysis.Journal of pharmacology & pharmacotherapeutics · 2013Article
- Retrospective evaluation of adverse drug reactions induced by antihypertensive treatment.Journal of pharmacology & pharmacotherapeutics · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Methotrexate (MTX) is a nonbiological disease-modifying antirheumatic drug that has shown both a good control of clinical disease and a good safety. Usually drug-drug interactions (DDIs) represent the most limiting factor during the clinical management of any disease, in particular when several drugs are coadministered to treat the same disease. In this paper, we report the interactions among MTX and the other drugs commonly used in the management of rheumatoid arthritis. Using Medline, PubMed, Embase, Cochrane libraries, and Reference lists, we searched for the articles published until June 30, 2012, and we reported the most common DDIs between MTX and antirheumatic drugs. In particular, clinically relevant DDIs have been described during the treatment with MTX and NSAIDs, for example, diclofenac, indomethacin, or COX-2 inhibitors, and between MTX and prednisone or immunosuppressant drugs (e.g., leflunomide and cyclosporine). Finally, an increase in the risk of infections has been recorded during the combination treatment with MTX plus antitumor necrosis factor- α agents. In conclusion, during the treatment with MTX, DDIs play an important role in both the development of ADRs and therapeutic failure.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.